Galderma will pay US$1.5 billion in cash to acquire 100% of ZO Skin Health, the physician-dispensed skin care brand founded by dermatologist Dr Zein Obagi in 2007, in a deal expected to close in the fourth quarter of 2026 or early 2027.

The numbers frame the strategic logic. ZO Skin Health recorded net sales of approximately $330 million in the 12 months to June 2026, distributed through more than 16,500 physicians, medical spas and online accounts across more than 40 countries. That's roughly $20,000 in annual net sales per dispensing account — a footprint Galderma clearly believes it can scale.

For context, ZO will sit alongside Cetaphil and Alastin in Galderma's dermatological skin care portfolio, which the Swiss company says positions it as "a partner of choice" for dermatologists, plastic surgeons and aesthetic professionals.

What does the deal actually cover?

The structure is straightforward:

• All-cash transaction, subject to customary adjustments, funded through existing cash reserves and bank financing
• Regulatory approvals and customary closing conditions still required before closing
• Lazard acts as Lead Financial Advisor, with JP Morgan as Financial Advisor and Ropes & Gray LLP as Legal Advisor

Galderma didn't disclose a valuation multiple, but at $1.5 billion against $330 million in trailing net sales, the implied multiple sits near 4.5x revenue — a figure that signals Galderma expects meaningful growth, not maintenance.

What did the CEOs say?

"This acquisition is another important step towards building the world's most innovative dermatology portfolio, strengthening our offering in an area where we already have significant capabilities," said Galderma CEO Flemming Ørnskov. He cited ZO's "strong clinical credentials, a distinctive protocol-based approach, and a trusted position among dermatologists and plastic surgeons," and added: "We see significant opportunities to reignite its growth through investment in innovation and commercial reach."

The word "reignite" is doing real work there. Galderma plans to increase commercial investment during the first year of ownership to "strengthen the foundation for renewed growth beginning in the second year following closing," according to a company statement.

Obagi himself endorsed the sale. "ZO Skin Health has been my life's work, and I could not be prouder to see it join a company that shares our commitment to science and the providers who trust us every day," he said. "I am confident we have found a home where our philosophy will endure, and grow for the benefit of dermatologists, plastic surgeons, aestheticians and the patients we serve."

How does ZO fit next to Alastin?

Galderma frames the two brands as complementary rather than overlapping. ZO's daily regimen-based portfolio centers on retinol- and acid-based protocols, while Alastin offers what the company calls a "highly differentiated peptide-based regenerative pre- and post-procedure offering." In practice, that means ZO covers daily maintenance and corrective regimens, while Alastin anchors the procedural corridor — the weeks before and after lasers, energy-based treatments and surgery.

The company's broader thesis, in Ørnskov's words: "With our dermatological skin care and injectable aesthetic businesses, Galderma is strategically positioned to compete for, and win, the attractive growth opportunities in the fast-growing medical-grade skin care segment."

What does this change for the margin picture?

Not much, and that's deliberate. Galderma expects the transaction to be slightly dilutive to the group's core EBITDA margin in 2027, then to reach a margin broadly comparable with the group's average from 2028 onwards. In other words: one heavier-investment year, then integration into the baseline.

The bottom line

For dermatologists and plastic surgeons who dispense ZO products, the practical question is whether Galderma's commercial investment — promised from year one — deepens product availability and support, or whether protocol-driven positioning softens under a larger portfolio. With closing still subject to regulatory approval and roughly a year away, clinicians will watch the integration roadmap, and whether ZO's protocol-based model survives intact under the same roof as Cetaphil's mass-market reach.